Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

@article{Lo2015DelayOT,
  title={Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.},
  author={Peter Lo and Suzanne E Dahlberg and Mizuki Nishino and Bruce Evan Johnson and Lecia V Sequist and David Michael Jackman and Pasi Antero J{\"a}nne and Geoffrey R. Oxnard},
  journal={Cancer},
  year={2015},
  volume={121 15},
  pages={2570-7}
}
BACKGROUND Erlotinib is a highly active epidermal growth factor receptor (EGFR) kinase inhibitor that is approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests that this drug may provide continued disease control after patients develop objective progression of disease (PD), although this has not been systematically studied to date. METHODS Patients who had Response Evaluation Criteria In Solid Tumors-defined PD who were participating in 3… CONTINUE READING